Recent development in the field of dual COX / 5-LOX inhibitors

Fabien Julémont, Jean-Michel Dogné, Bernard Pirotte, Xavier de Leval

Research output: Contribution to journalArticlepeer-review


Cyclooxygenases and lipoxygenase are key enzymes in the arachidonic acid metabolism. Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of anti-inflammatory activities. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of non-selective COX inhibitors.
Original languageEnglish
Pages (from-to)633-8
Number of pages6
JournalMini-reviews in medicinal chemistry
Issue number6
Publication statusPublished - Aug 2004


  • Arachidonic Acid
  • Cyclooxygenase Inhibitors
  • Humans
  • Lipoxygenase
  • Lipoxygenase Inhibitors
  • Prostaglandin-Endoperoxide Synthases
  • Signal Transduction
  • Sulfonamides


Dive into the research topics of 'Recent development in the field of dual COX / 5-LOX inhibitors'. Together they form a unique fingerprint.

Cite this